Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation
AbstractTrichomoniasis, caused by the parasitic protozoan Trichomonas vaginalis, is the most common non-viral sexually-transmitted disease, and there can be severe complications from trichomoniasis. Antibiotic resistance in T. vaginalis is increasing, but there are currently no alternatives treatment options. There is a need to discover and develop new chemotherapeutic alternatives. Plant-derived natural products have long served as sources for new medicinal agents, as well as new leads for drug discovery and development. In this work, we have carried out an in silico screening of 952 antiprotozoal phytochemicals with specific protein drug targets of T. vaginalis. A total of 42 compounds showed remarkable docking properties to T. vaginalis methionine gamma-lyase (TvMGL) and to T. vaginalis purine nucleoside phosphorylase (TvPNP). The most promising ligands were polyphenolic compounds, and several of these showed docking properties superior to either co-crystallized ligands or synthetic enzyme inhibitors. View Full-Text
Share & Cite This Article
Setzer, M.S.; Byler, K.G.; Ogungbe, I.V.; Setzer, W.N. Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation. Sci. Pharm. 2017, 85, 5.
Setzer MS, Byler KG, Ogungbe IV, Setzer WN. Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation. Scientia Pharmaceutica. 2017; 85(1):5.Chicago/Turabian Style
Setzer, Mary S.; Byler, Kendall G.; Ogungbe, Ifedayo V.; Setzer, William N. 2017. "Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation." Sci. Pharm. 85, no. 1: 5.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.